Insulin resistance predicts steatosis and fibrosis in morbidly obese patients undergoing bariatric surgery

Journal of Investigative Medicine

Volumn 60, Issue 7, 2012, Pages 1005-1008

  Aller, Rocio ^a   De Luis, Daniel ^a   Pacheco, David ^a   Velasco, Maria Concepcion ^a   Izaola, Olatz ^a   Sagrado, Manuel Gonzalez ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Adipokines; Bariatric surgery; Insulin resistance; Morbid obesity; Nonalcoholic fatty liver disease

Indexed keywords

ADIPONECTIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; ADIPOCYTOKINE;

ADULT; ARTICLE; BARIATRIC SURGERY; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DISEASE COURSE; ENZYME ACTIVITY; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MALE; MORBID OBESITY; PREDICTION; TERTIARY HEALTH CARE; TRIACYLGLYCEROL BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN TISSUE; PROTEIN BLOOD LEVEL; SURGICAL PATIENT; TERTIARY CARE CENTER;

ADULT; BARIATRIC SURGERY; CROSS-SECTIONAL STUDIES; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; OBESITY, MORBID; SPAIN;

EID: 85006176720     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31826509f2     Document Type: Article

References (36)

1. Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol. 2007;23:193-198.
2. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
3. Chitturi S, Abeygunasekera S, Farell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373-379.
4. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513-1517.
5. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008;27:412-421.
6. Steppan CM, Bailey ST, Bhat S. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
7. Fernandez Real JM, Vendrell J, Ricart W. Circulating adiponectin and plasma fatty acid profile. Clin Chem. 2005;51:603-609.
8. Shimomoura I, Hammer RE, Ikemoto S. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401:73-76.
9. Matsuzawa Y. Adipocytokines: emerging therapeutic targets. Curr Atheroscler Rep. 2005;7:58-62.
10. Aller R, de Luis DA, Fernandez L, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dis Sci. 2008;53:1088-1092.
11. Angulo P. NAFLD, obesity, and bariatric surgery. Gastroenterology. 2006;130:1848-1852.
12. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab. 2005;90:3498-3504.
13. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology. 2002;36:403-409.
14. Heilbronn LK, Rood J, Janderova L, et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin EndocrinolMetab. 2004;89:1844-1848.
15. Kaser S, Moschen A, Cayon A, et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut. 2005;54:117-121.
16. Le D, Marks D, Lyle E, et al. Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc. 2007;21: 1593-1599.
17. Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol. 2005; 152:113-118.
18. Pagano C, Soardo G, Pilon C, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab. 2006;91:1081-1086.
19. Targher G, Bertolini L, Rodella S, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) . 2006;64:679-683.
20. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol. 2008;43:1128-1136.
21. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and beta-cell function from plasma fasting glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
22. Mataix VJ, Manas AM. Tablas de Composicio'n de Alimentos Espanoles. 3rd ed. Granada, Spain: University of Granada; 1998.
23. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3-16.
24. Marchesini G, Brizi M, Morselli-Labate A, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107:450-454.
25. Sanyal AJ, Campbell Sargent C, Mirshashi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001;120:1183-1192.
26. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2000;30:48-53.
27. Vega GL, Chandalia M, Szczepaniak LS, et al. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology. 2007;46:716-722.
28. Venturi C, Zoppini G, Zamboni C, et al. Insulin sensitivity and hepatic steatosis in obese subjects with normal glucose tolerance. Nutr Metab Cardiovasc Dis. 2004;14:200-204.
29. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004;114:147-152.
30. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol. 2008;43:1128-1136.
31. Yalniz M, Bahcecioglu IH, Ataseven H, et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm. 2006;2006:34295.
32. Shklyaev S, Aslanidi G, Tennant M, et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci U S A. 2003;100:14217-14222.
33. Fernandez Real JM, Vendrell J, Ricart W. Circulating adiponectin and plasma fatty acid profile. Clin Chem. 2005;51:603-609.
34. Yagmur E, Trautwein C, Gressner AM, et al. Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver disease. Am J Gastroenterol. 2006;101:1244-1252.
35. Perseghin G, Lattuada G, De Cobelli F, et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab. 2006;91:5122-5125.
36. Cho YK, Lee WY, Oh SY, et al. Factors affecting the serum levels of adipokines in Korean male patients with nonalcoholic fatty liver disease. Hepatogastroenterology. 2007;54:1512-1514.